FDA News

Featured Article
Needle-Free Injection Product Recalled
Ferring Pharmaceuticals Inc is recalling nearly 2000 ZOMA-Jet demonstration kits, citing defective delivery systems.
Psoriasis Drug Recalled
A recall is active for a prescription medication used to treat adults with moderate to severe plaque psoriasis and adults with active psoriatic arthritis.
Class I Recall for Injection
Customer reports of product crystallization have prompted a Class I recall of acyclovir sodium injection.

Newsfeed

Needle-Free Injection Product Recalled
Psoriasis Drug Recalled
Class I Recall for Injection
Irrigation Solution Recalled
Proton Pump Inhibitor Recalled
Acid Reducer Recalled
Hypotension Injection Recalled
Class I and II Recalls for Diuretic
View More

Insights

Reviewing the Recent FDA Approval of Venclexta for AML
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
FDA Requires Stronger Warning Labels for Benzodiazepines
Michael Cawley, PharmD, discusses the recent news from the FDA on benzodiazepines, which includes new boxed warnings for the use of these medications, and changes to the prescribing information and patient medication guides.
Anesthetic Injection Recalled
A Class II recall is active for a prescription analgesic injection used during anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period.
View More

Interactive Features

CV Deaths, Hospitalizations Reduced for Patients Treated With Farxiga
In this episode of PopHealth Perspectives, Kiersten Combs, vice president, US Cardiovascular and Metabolic Disease (US CVMD) and Naeem Khan, MD, vice president, medical, US CVMD, AstraZeneca, discuss the recent approval of Farxiga (dapagliflozin),…
Positive Results Support Approval of Treatment for Patients With Multiple Myeloma
Saad Usmani, MD, discusses the recent approval of daratumumab subcutaneous formulation for patients with multiple myeloma, and explains the major benefits of this treatment for this patient population.
Breaking Down the Expanded Approval of a CLL Treatment
In this podcast, Andree Amelsberg, vice president of US Medical Affairs Oncology and Hematology at Janssen, and Danelle James, Imbruvica clinical science lead at Pharmacyclics LLC, an AbbVie company, discuss the recent expanded approval of Imbruvica…
Identifying Recent Pain Medication Recalls
Which narcotic pain medication—used to treat moderate to severe pain—has been recalled in the last two FDA Enforcement Reports?
View More
Back to Top